PhytoVenomics provides an AI-driven platform that automates the design and optimization of therapeutic antibody candidates. Using generative models and deep‑learning predictors, it generates novel sequences, scores affinity and developability, and streamlines humanization, enabling pharma, biotech, and academic teams to accelerate antibody discovery while reducing experimental screening costs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody drug discovery relies on extensive experimental screening and serendipitous discovery, leading to long timelines, high costs, and low success rates.
Solution
PhytoVenomics offers an AI-driven antibody design platform that automates the generation and optimization of therapeutic antibody candidates. The system uses machine‑learning models trained on large antibody datasets to predict binding affinity, developability, and manufacturability, enabling researchers to design antibodies in silico before any wet‑lab work. By providing rapid iteration cycles and data‑rich predictions, the platform reduces the need for costly high‑throughput screening and accelerates the path from target identification to preclinical candidate.
Target Audience
Primary customers are pharmaceutical companies, biotech firms, and academic research groups engaged in therapeutic antibody development.
Features
- Generative AI models that propose novel antibody sequences tailored to specific antigens
- In silico affinity and developability scoring using deep‑learning predictors
- Automated humanization and de‑immunization workflows to improve safety profiles
- Integration with cloud‑based simulation tools for structural validation and epitope mapping
- API and UI for seamless export of candidate sequences to laboratory synthesis pipelines